PHYSIOMANCE NASH brings for 6 tablets :
- 400 mg of choline bitartrate VitaCholineTM, which helps to maintain normal liver function;
- 300 mg rosemary extract titrated to 120 mg ursolic acid, which promotes hepatobiliary drainage, helps to support normal liver function and supports liver and biliary function;
- 250 mg milk thistle extract titrated at 200 mg silymarin, which contributes to the detoxification potential of the liver, its protection and proper functioning;
- 20 mg glutathione, provided in its most bioavailable form: S-acetyl-L-glutathione;
- 50% of RI* in natural vitamin E, which contributes to the protection of cells against oxidative stress;
- 2 g of L-ornithine-L-aspartate, 50 mg of N-acetylcysteine and 4 mg of lycopene, to complete the formula.
*RI: Reference Intakes
Why choose PHYSIOMANCE NASH from the THERASCIENCE Laboratory ?
For its complete formula combining 7 bio-active ingredients (L-ornithine-L-aspartate, choline bitartrate, rosemary, milk thistle, N-acetylcysteine, glutathione and lycopene) with natural vitamin E, contributing to the proper functioning of the liver.
Expert opinion
Liver pathologies of lipid overload, commonly known as "soda disease" or "foie gras disease", are now the main cause of chronic liver disease in the West in the absence of excessive alcohol consumption.
Metabolic diseases with a nutritional and environmental component, these pathologies range from simple non-alcoholic steatosis (NAFLD or Non-Alcoholic Fatty Liver Disease), a reversible condition if treated in time, to non-alcoholic steatohepatitis (NASH or Non-Alcoholic Steato Hepatitis), which can develop into fibrosis or even cirrhosis, serious and non-reversible pathologies.
NAFLD is characterised by an abnormal accumulation of triglycerides in at least 5% of hepatocytes. It most often develops without any apparent clinical signs. It is strongly correlated with obesity and metabolic syndrome, and is independently associated with increased cardiovascular morbidity and mortality.
The NAFLD epidemic affects all countries. In France, it affects more than 20% of the population, including an increasing number of overweight adolescents and young people, underlining the importance of early screening and treatment.
In 12-40% of cases, NAFLD is moving towards NASH. Prevention is therefore essential.
As the various pharmacological treatments proposed have so far shown only limited effectiveness, the implementation of hygienic and dietetic measures, including the use of appropriate nutritional supplements, remains a preferred treatment strategy.
